Study shows flash glucose monitors help youth with type1 diabetes

A world-first Otago study has revealed flash glucose monitors help youth with type 1 diabetes better monitor their blood sugar levels, however it does not improve glucose control.

A team of researchers co-led by Associate Professor Ben Wheeler and Dr Sara Boucher from the University of Otago's Department of Women and Children's Health conducted a six-month trial among adolescents aged 13-20 years with a history of suboptimal glycaemic control.

For the first time we have run a large trial in this population of people, with potentially the most to gain from new diabetes therapies, but usually excluded from diabetes research," says Associate Professor Wheeler.

Ben Wheeler, Associate Professor, University of Otago

Flash glucose monitoring, which was introduced in New Zealand in 2017, allows people to wear a small sensor just under the skin on their upper arm (replaced every 14 days) and use a separate handheld device to scan the sensor.

When the reader is held close to the sensor, the sensors sends a current glucose level, and both an eight-hour retrospective glucose level graph and a predictions of glucose level increases or decreases.

The research team compared monitoring results of 64 study participants divided into two groups - one group used flash glucose monitoring, and the other used finger-prick monitoring.

Encouragingly, Associate Professor Wheeler says study participants who were given the flash glucose monitors more than doubled their glucose level monitoring frequency.

At the start of the study period, both groups, on average, were checking their levels less than twice per day, which is below the recommended minimum four checks per day.

After six months, those using flash monitors were checking their levels, on average, 3.8 times per day, including scanning and finger pricking as needed, whereas the control group was checking their glucose levels, on average, 1.4 times per day

Surprisingly, researchers discovered the group using the flash monitoring technology had not improved their glucose control and quality of life significantly more than the control group after six months.

Despite the improved glucose-checking technology, and overwhelmingly positive participant and family experiences, improving psychosocial outcomes will require more intensive methods, Associate Professor Wheeler says.

"What we have also shown, is to translate these positive aspects into healthier diabetes, we need something more - either more support, or more automated technology that helps give insulin as well as just monitor."

Dr Sara Boucher says youth traditionally have the least healthy glucose control.

"To date, we are struggling to find options to help improve this.

"The aim of this study was to see if using flash glucose monitors as a replacement for blood glucose monitoring would help youth with type 1 diabetes and unhealthy diabetes achieve healthier diabetes control over a six-month period."

The next research steps include more support for youth, and a focus on diet and sleep, being led by Dr Boucher, but also looking at increasing automation, such as artificial pancreas systems that combine less invasive monitoring technology with computer-driven automated insulin delivery.

Background information

More than 250,000 people in New Zealand have diabetes, and of those, Diabetes New Zealand estimates 10 per cent have type 1 diabetes.

It is usually diagnosed in childhood, and people with diabetes must constantly monitor blood glucose levels and inject insulin to live, as their bodies have stopped producing it naturally.

However young people don't always monitor their glucose levels as frequently as they should, due to a desire to fit in with their peers, and also the physical discomfort associated with the more commonly-used finger pricking monitoring method, which needs to be done up to 10 times a day.

People using flash glucose monitors might end up needing to use the finger-pricking method once or twice a week.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes